📣 VC round data is live. Check it out!
- Public Comps
- Surgical Science
Surgical Science Valuation Multiples
Discover Surgical Science's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech and more.
Surgical Science Overview
About Surgical Science
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company’s core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
Founded
1999
HQ

Employees
274
Website
Financials (LTM)
EV
$113M
Valuation Multiples
Start free trialSurgical Science Financials
Surgical Science reported last 12-month revenue of $108M and EBITDA of $19M.
In the same LTM period, Surgical Science generated $58M in gross profit, $19M in EBITDA, and $9M in net income.
Revenue (LTM)
Surgical Science P&L
In the most recent fiscal year, Surgical Science reported revenue of $109M and EBITDA of $20M.
Surgical Science is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 19%, and net margin of 7%.
Financial data powered by Morningstar, Inc.
Surgical Science Stock Performance
Surgical Science has current market cap of $185M, and enterprise value of $113M.
Market Cap Evolution
Surgical Science's stock price is $3.62.
Surgical Science share price decreased by 8.7% in the last 30 days, and by 78.1% in the last year.
Surgical Science has an EPS (earnings per share) of $0.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $185M | -4.4% | -8.7% | 9.1% | -78.1% | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSurgical Science Valuation Multiples
Surgical Science trades at 1.0x EV/Revenue multiple, and 6.1x EV/EBITDA.
EV / Revenue (LTM)
Surgical Science Financial Valuation Multiples
As of June 3, 2026, Surgical Science has market cap of $185M and EV of $113M.
Surgical Science has a P/E ratio of 21.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Surgical Science Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Surgical Science Margins & Growth Rates
Surgical Science decreased revenue by 2% but EBITDA grew by 5% in the last fiscal year.
In the most recent fiscal year, Surgical Science reported gross margin of 65%, EBITDA margin of 19%, and net margin of 7%.
Surgical Science Margins
Surgical Science Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Surgical Science Operational KPIs
Surgical Science's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Surgical Science's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surgical Science's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Surgical Science Competitors
Surgical Science competitors include Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech, Lucid Diagnostics, Medinice, Asterasys, Aroa Biosurgery, Ilex Medical and RxSight.
Most Surgical Science public comparables operate across Medical Devices, VR & AR, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 1.4x | 1.4x | 6.4x | 6.3x | |||
| 1.6x | 1.5x | 33.0x | 24.0x | |||
| 2.2x | 2.1x | 13.6x | 13.7x | |||
| 44.1x | 35.6x | (3.7x) | (4.0x) | |||
| - | - | (111.9x) | - | |||
| 7.5x | 6.3x | 22.7x | 18.2x | |||
| 2.8x | 2.5x | 81.9x | 21.4x | |||
This data is available for Pro users. Sign up to see all Surgical Science competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Surgical Science
Surgical Science has acquired 3 companies to date.
Last acquisition by Surgical Science was on July 29th 2021. Surgical Science acquired Simbionix for $305M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Surgical Science
| Description | Simbionix is a Cleveland-headquartered provider of medical simulation systems for surgical training, offering simulators for laparoscopic, endovascular, endoscopic, bronchoscopy, and endourology procedures. Its Learning Management System tracks trainee performance metrics, while the PROcedure Rehearsal Studio generates patient-specific 3D models from CT scans. Distributed in the Middle East, South America, Asia-Pacific, and Europe, Simbionix serves surgeons, nurses, and technicians globally. Founded in 1997 with R&D in Israel, the company was acquired by 3D Systems in 2016, enhancing VR-based rehearsals for over 1,000 training centers. | Mimic Technologies is a Seattle-headquartered leader in robotic surgery simulation and training. The company supplies software, hardware, and curricula to institutions worldwide, advancing minimally invasive procedures through realistic simulators that enhance surgeon skills and patient safety. | SenseGraphics is a Stockholm-based software platform developer founded in 2004, specializing in H3D API for integrating haptics and 3D stereo visualization into applications. The dual-licensed tool supports X3D and OpenGL standards, compatible with haptic devices from SensAble Technologies, Novint, and Force Dimension. Deployed in medical simulators like MedaPhor ScanTrainer and MOOG Simodont Dental Trainer, as well as veterinary and rehabilitation systems, H3D API facilitates force feedback in research, robotics, and training. SenseGraphics offers consulting, training, and custom hardware alongside its core development toolkit. |
| HQ Country | |||
| HQ City | Cleveland, OH | Seattle, WA | Stockholm |
| Deal Date | 29 Jul 2021 | 20 Jan 2021 | 1 Jan 2019 |
| Valuation | $305M | $18M | $29M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Surgical Science acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Surgical Science
| When was Surgical Science founded? | Surgical Science was founded in 1999. |
| Where is Surgical Science headquartered? | Surgical Science is headquartered in Sweden. |
| How many employees does Surgical Science have? | As of today, Surgical Science has over 274 employees. |
| Who is the CEO of Surgical Science? | Surgical Science's CEO is Tom Englund. |
| Is Surgical Science publicly listed? | Yes, Surgical Science is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Surgical Science? | Surgical Science trades under SUS ticker. |
| When did Surgical Science go public? | Surgical Science went public in 2017. |
| Who are competitors of Surgical Science? | Surgical Science main competitors include Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech, Lucid Diagnostics, Medinice, Asterasys, Aroa Biosurgery, Ilex Medical, RxSight. |
| What is the current market cap of Surgical Science? | Surgical Science's current market cap is $185M. |
| What is the current revenue of Surgical Science? | Surgical Science's last 12 months revenue is $108M. |
| What is the current revenue growth of Surgical Science? | Surgical Science revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Surgical Science? | Current revenue multiple of Surgical Science is 1.0x. |
| What is the current EBITDA of Surgical Science? | Surgical Science's last 12 months EBITDA is $19M. |
| What is Surgical Science's EBITDA margin? | Surgical Science's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Surgical Science? | Current EBITDA multiple of Surgical Science is 6.1x. |
| What is the current FCF of Surgical Science? | Surgical Science's last 12 months FCF is ($801K). |
| What is Surgical Science's FCF margin? | Surgical Science's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Surgical Science? | Current FCF multiple of Surgical Science is (141.5x). |
| How many companies Surgical Science has acquired to date? | As of June 2026, Surgical Science has acquired 3 companies. |
| What was the largest acquisition by Surgical Science? | $305M acquisition of Simbionix on 29th July 2021 was the largest M&A Surgical Science has done to date. |
| What companies Surgical Science acquired? | Surgical Science acquired Simbionix, SenseGraphics, and Mimic Technologies. |
| In how many companies Surgical Science has invested to date? | Surgical Science hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Surgical Science
Lists including Surgical Science
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

